DGX Quest Diagnostics (DGX) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-medical laboratories · CIK 0001022079
Congress · 1Form 144 · 3
Insider buyers, 180 days
0
Funds added, last quarter
550
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $3.6M priced
What the filings say about DGX
Insiders, 180 days
-$11.9M net sold
4 sellers · 57% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2025-11-03
Planned sales (Form 144), 90 days
$8.2M
3 notices
Quest Diagnostics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, QUEST DIAGNOSTICS INC insiders sold a net $11.9M of stock across 140 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Jun 1, 2026.
- The trade is 8.2% of the 122,423 shares held after it.
- 1 other insider sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and President Davis J. E. sold about $2.4M of DGX under a 10b5-1 plan on Sep 1, 2026; 1 other insider sold within 30 days and 550 funds added in the latest 13F quarter.Context
- 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Mar 5, 2026.
- The trade is 36.2% of the 44,224 shares held after it.
- 1 other insider sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & General Counsel PREVOZNIK MICHAEL E sold about $3.9M of DGX under a 10b5-1 plan on Aug 28, 2026; 1 other insider sold within 30 days and 550 funds added in the latest 13F quarter.Context
- 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Mar 5, 2026.
- The trade is 16.4% of the 37,987 shares held after it.
- 1 other insider sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & General Counsel PREVOZNIK MICHAEL E sold about $1.5M of DGX under a 10b5-1 plan on Aug 28, 2026; 1 other insider sold within 30 days and 550 funds added in the latest 13F quarter.Context
- 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Mar 5, 2026.
- The trade is 1.1% of the 37,557 shares held after it.
- 1 other insider sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & General Counsel PREVOZNIK MICHAEL E sold about $105.1K of DGX under a 10b5-1 plan on Aug 28, 2026; 1 other insider sold within 30 days and 550 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Nov 18, 2025.
- The trade is 15.5% of the 10,335 shares held after it.
- No other insider sold within 30 days.
- 550 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP & Chief Commercial Officer DELANEY MARK E sold about $376.3K of DGX on Jul 28, 2026; 550 funds added in the latest 13F quarter.140 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$11.9M over 180 days
-$7.9M over 90 days
below 71% of Healthcare Services
Congress
1 member bought in the last year
the lowest in Healthcare Services
Funds
550 funds bought in last quarter
more than 99% of Healthcare Services
Revenue
+11.8% year over year
more than 51% of Healthcare Services
Margin
9.0% net margin
more than 86% of Healthcare Services
Buybacks
$252.0M repurchased, FY to 2026-09-30
more than 77% of Healthcare Services
Short interest
3.3% of the float short (float per yahoo 2026-10-27) · 3.4 days to cover · settled 2026-10-15
more than 50% of Healthcare Services
What changed in the last 30 days
Oct 26Director PFEIFFER GARY M filed to sell $292.3K by Oct 26 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch DGX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+34.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns DGX: institutional holders (13F)
13F holdings, latest reported quarter
9,275,411 sh
$2.0B
7,233,394 sh
$1.5B
6,131,045 sh
$1.3B
5,516,643 sh
$1.2B
4,744,473 sh
$1.0B
Congress trades in DGX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-11-03 · disclosed 38 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 279 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 279 days later
$1,001 - $15,000
Sold 2025-07-24 · disclosed 173 days later
$1,001 - $15,000
Bought 2025-04-28 · disclosed 260 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
DGX planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
PFEIFFER GARY M
Filed 2026-10-26
$292.3K
Davis J. E.
Filed 2026-09-01
$2.4M
PREVOZNIK MICHAEL E
Filed 2026-08-28
$5.5M
DELANEY MARK E
Filed 2026-07-28
$376.3K
DGX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Davis Opportunity Fund
$43.0M position · as of 2026-06-30
6.6%
Saratoga Large Capitalization Value Portfolio
$820.1K position · as of 2026-05-31
5.4%
M.D. Sass Concentrated Value ETF
$4.1M position · as of 2026-05-31
5.3%
Davis Balanced Fund
$15.7M position · as of 2026-06-30
4.9%
ROCK OAK CORE GROWTH FUND
$504.5K position · as of 2026-07-31
3.7%
iShares U.S. Healthcare Providers ETF
$41.3M position · as of 2026-06-30
3.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Veterans Affairs
PRIMARY REFERENCE LABORATORY TESTING / COURIER SERVICES / PHLEBOTOMY · 2025-07-01
$10.1M
Department Of Veterans Affairs
VISN 7 REFERENCE LAB SERVICES · 2025-10-01
$7.2M
Department Of Veterans Affairs
FY27 TASK ORDER - 10/1/2026 - 6/30/2027 · 2026-10-01
$7.2M
Department Of Veterans Affairs
REF LAB SERVICES VISN 7 · 2026-04-01
$6.6M
Department Of Veterans Affairs
QUEST DIAGNOSTICS - HEMATOLOGY MOLECULAR TESTING SERVICES · 2026-09-30
$3.5M
Department Of Veterans Affairs
VISN 12 MULTI-SITE REFERENCE LABORATORY TESTING SERVICES FY27 TO · 2026-10-01
$3.1M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Quest Diagnostics Incorporated Political Action Committee
Cycle 2026 · $349K spent
$379.6K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · James EDavis
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$12.7M
$9.4M
$2.9M
+40%
+32%
2021
$14.6M
$49.2M
$3.4M
+69%
+43%
2020
$14.1M
$31.0M
$3.6M
+14%
+13%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $11.9M sold by insiders over 180 days, 550 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $8.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
DGX financials
Revenue growth
+11.8%
XBRL, annual
Net margin
9.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$11.8B
four quarters, 2025-10-01 to 2026-09-30
Revenue, TTM DGX
| FY Dec 2025 | $11.0B |
| FY Dec 2024 | $9.9B |
| FY Dec 2023 | $9.3B |
| FY Dec 2022 | $9.9B |
| FY Dec 2021 | $10.8B |
| Sep 2026 | $3.1B |
| Jun 2026 | $3.0B |
| Mar 2026 | $2.9B |
| Dec 2025 | $2.8B |
| Sep 2025 | $2.8B |
| Jun 2025 | $2.8B |
| Mar 2025 | $2.7B |
| Dec 2024 | $2.6B |
At each fiscal year end
Single quarter
Net margin, TTM
+9.5%
net income over revenue, 2025-10-01 to 2026-09-30
Net margin, TTM DGX
| FY Dec 2025 | +9.0% |
| FY Dec 2024 | +8.8% |
| FY Dec 2023 | +9.2% |
| FY Dec 2022 | +9.6% |
| FY Dec 2021 | +18.5% |
| Sep 2026 | +10.1% |
| Jun 2026 | +10.5% |
| Mar 2026 | +8.7% |
| Dec 2025 | +8.7% |
| Sep 2025 | +8.7% |
| Jun 2025 | +10.2% |
| Mar 2025 | +8.3% |
| Dec 2024 | +8.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$1.4B
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Free cash flow, TTM DGX
| FY Dec 2025 | $1.4B |
| FY Dec 2024 | $909.0M |
| FY Dec 2023 | $864.0M |
| FY Dec 2022 | $1.3B |
| FY Dec 2021 | $1.8B |
| Sep 2026 | $445.0M |
| Jun 2026 | $459.0M |
| Mar 2026 | $164.0M |
| Dec 2025 | $307.0M |
| Sep 2025 | $419.0M |
| Jun 2025 | $436.0M |
| Mar 2025 | $197.0M |
| Dec 2024 | $341.0M |
At each fiscal year end
Single quarter
Debt to equity
0.73x
long-term 2026-09-30 plus current 2026-09-30; equity 2026-09-30
Debt to equity DGX
| FY Dec 2025 | 0.79x |
| FY Dec 2024 | 0.92x |
| FY Dec 2023 | 0.75x |
| FY Dec 2022 | 0.68x |
| FY Dec 2021 | 0.62x |
| Sep 2026 | 0.73x |
| Jun 2026 | 0.75x |
| Mar 2026 | 0.77x |
| Dec 2025 | 0.79x |
| Sep 2025 | 0.78x |
| Jun 2025 | 0.78x |
| Mar 2025 | 0.85x |
| Dec 2024 | 0.92x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.35x
TTM operating cash flow over long-term 2026-09-30 plus current 2026-09-30
Cash flow to debt DGX
| FY Dec 2025 | 0.33x |
| FY Dec 2024 | 0.21x |
| FY Dec 2023 | 0.27x |
| FY Dec 2022 | 0.43x |
| FY Dec 2021 | 0.56x |
| Sep 2026 | 0.35x |
| Jun 2026 | 0.34x |
| Mar 2026 | 0.33x |
| Dec 2025 | 0.33x |
| Sep 2025 | 0.33x |
| Jun 2025 | 0.30x |
| Mar 2025 | 0.25x |
| Dec 2024 | 0.21x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+15.2%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on equity DGX
| FY Dec 2025 | +14.2% |
| FY Dec 2024 | +13.3% |
| FY Dec 2023 | +14.0% |
| FY Dec 2022 | +15.3% |
| FY Dec 2021 | +30.2% |
| Sep 2026 | +15.2% |
| Jun 2026 | +14.4% |
| Mar 2026 | +14.3% |
| Dec 2025 | +14.2% |
| Sep 2025 | +13.8% |
| Jun 2025 | +13.7% |
| Mar 2025 | +13.4% |
| Dec 2024 | +13.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+6.8%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets DGX
| FY Dec 2025 | +6.1% |
| FY Dec 2024 | +5.8% |
| FY Dec 2023 | +6.4% |
| FY Dec 2022 | +7.2% |
| FY Dec 2021 | +14.4% |
| Sep 2026 | +6.8% |
| Jun 2026 | +6.5% |
| Mar 2026 | +6.3% |
| Dec 2025 | +6.1% |
| Sep 2025 | +6.0% |
| Jun 2025 | +6.4% |
| Mar 2025 | +6.0% |
| Dec 2024 | +5.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+10.7%
operating income after a 22.9% effective tax rate, over long-term 2026-09-30 plus current 2026-09-30 plus average of 2025-09-30 and 2026-09-30 minus cash
Return on invested capital DGX
| FY Dec 2025 | +9.7% |
| FY Dec 2024 | +8.5% |
| FY Dec 2023 | +9.6% |
| FY Dec 2022 | +11.8% |
| FY Dec 2021 | +19.1% |
| Sep 2026 | +10.7% |
| Jun 2026 | +10.0% |
| Mar 2026 | +9.8% |
| Dec 2025 | +9.7% |
| Sep 2025 | +9.7% |
| Jun 2025 | +9.2% |
| Mar 2025 | +8.8% |
| Dec 2024 | +8.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+11.7%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
Return on capital employed DGX
| FY Dec 2025 | +11.1% |
| FY Dec 2024 | +10.3% |
| FY Dec 2023 | +10.7% |
| FY Dec 2022 | +12.3% |
| FY Dec 2021 | +19.8% |
| Sep 2026 | +11.7% |
| Jun 2026 | +11.2% |
| Mar 2026 | +11.2% |
| Dec 2025 | +11.1% |
| Sep 2025 | +10.9% |
| Jun 2025 | +11.4% |
| Mar 2025 | +10.7% |
| Dec 2024 | +10.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
24.20x
close 2026-10-26 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
P/E, trailing DGX
| FY Dec 2025 | 19.83x |
| FY Dec 2024 | 19.62x |
| FY Dec 2023 | 18.41x |
| FY Dec 2022 | 19.63x |
| FY Dec 2021 | 11.10x |
| Sep 2026 | 23.21x |
| Jun 2026 | 22.50x |
| Mar 2026 | 21.66x |
| Dec 2025 | 19.83x |
| Sep 2025 | 22.37x |
| Jun 2025 | 21.51x |
| Mar 2025 | 21.39x |
| Dec 2024 | 19.62x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$31.5B
market value at close 2026-10-26 on 2026-10-15 shares, plus long-term 2026-09-30 plus current 2026-09-30, minus cash 2026-09-30
Enterprise value DGX
| FY Dec 2025 | $24.6B |
| FY Dec 2024 | $22.5B |
| FY Dec 2023 | $19.5B |
| FY Dec 2022 | $21.5B |
| FY Dec 2021 | $24.4B |
| Sep 2026 | $30.5B |
| Jun 2026 | $28.5B |
| Mar 2026 | $26.8B |
| Dec 2025 | $24.6B |
| Sep 2025 | $26.6B |
| Jun 2025 | $25.4B |
| Mar 2025 | $24.4B |
| Dec 2024 | $22.5B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.1%
TTM free cash flow over market value at close 2026-10-26
FCF yield DGX
| FY Dec 2025 | +7.0% |
| FY Dec 2024 | +5.4% |
| FY Dec 2023 | +5.6% |
| FY Dec 2022 | +7.4% |
| FY Dec 2021 | +8.6% |
| Sep 2026 | +5.3% |
| Jun 2026 | +5.7% |
| Mar 2026 | +6.2% |
| Dec 2025 | +7.0% |
| Sep 2025 | +6.5% |
| Jun 2025 | +6.1% |
| Mar 2025 | +5.6% |
| Dec 2024 | +5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.36x
P/E over trailing EPS growth of 18%: four quarters to 2026-09-30 against the four to 2025-09-30
PEG, trailing DGX
| FY Dec 2025 | 1.44x |
| FY Dec 2024 | 7.35x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.23x |
| Sep 2026 | 1.30x |
| Jun 2026 | 1.76x |
| Mar 2026 | 1.50x |
| Dec 2025 | 1.44x |
| Sep 2025 | 1.54x |
| Jun 2025 | 1.70x |
| Mar 2025 | 3.31x |
| Dec 2024 | 7.35x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $11.0B | $9.9B | $9.3B | $9.9B |
| Operating income | $1.6B | $1.3B | $1.3B | $1.4B |
| Net income | $992.0M | $871.0M | $854.0M | $946.0M |
| EPS (diluted) | 8.75 | 7.69 | 7.49 | 7.97 |
| Operating cash flow | $1.9B | $1.3B | $1.3B | $1.7B |
| Cash | $420.0M | $549.0M | $686.0M | $315.0M |
| Long-term debt | $5.2B | $5.6B | $4.4B | $4.0B |
| Buybacks | $450.0M | $151.0M | $275.0M | $1.4B |
| Dividends paid | $353.0M | $331.0M | $314.0M | $305.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
DGX Stock Sonar score 6/7 axes
Find similar shapesCompareDGX ranks highest on profitability (68th percentile) and institutional and government (66th), and lowest on insider conviction (22nd), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
DGX filings, in plain words
Are Quest Diagnostics insiders buying or selling DGX?
In the 180 days to 2026-10-28, Quest Diagnostics insiders were net sellers, a net $11.9M across purchases and sales reported on Form 4, by 4 sellers.
Have members of Congress traded DGX?
Yes. In the year to 2026-10-28, 1 House member disclosed buying DGX and 1 House member disclosed selling it; the latest on record is a sale by Julie Johnson dated 2025-11-03.
Are there planned insider sales of DGX?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $8.2M of stock; the latest, by PFEIFFER GARY M, was filed 2026-10-26.
Read the full summary
In the 180 days to 2026-10-28, Quest Diagnostics insiders were net sellers of DGX, a net $11.9M across purchases and sales reported on Form 4 by 4 sellers. 57% of the 7 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying DGX and 1 member disclosed selling it; the latest on record is a sale by Julie Johnson dated 2025-11-03. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $8.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
